Pharma & Life Sciences

Sintilimab bevacizumab gastric cancer trial Zhongshan Hospital

National Library of Medicine registered a new clinical trial (NCT07515625) on ClinicalTrials.gov evaluating sintilimab combined with bevacizumab for treating advanced gastric or gastroesophageal junction adenocarcinoma at Zhongshan Hospital in China. The single-arm Phase 2 study will enroll approximately 20 participants.

Zhejiang University FAP CAR-DC trial, end-stage dilated cardiomyopathy

The National Library of Medicine registered a new Phase 1 clinical trial (NCT07516288) on ClinicalTrials.gov, sponsored by Zhejiang University in China. The trial evaluates FAP CAR-DC cell therapy for patients with end-stage dilated cardiomyopathy. The study appears in the ClinicalTrials.gov public registry as an informational record for transparency and public awareness.

Iparomlimab tovorilimab bevacizumab mesothelioma trial

NIH registered a new Phase 2 clinical trial (NCT07514793) on ClinicalTrials.gov evaluating the combination of iparomlimab, tovorilimab, and bevacizumab for the treatment of mesothelioma. The trial is sponsored by Memorial Sloan Kettering Cancer Center and appears to be an open-label study investigating this immunotherapy combination. ClinicalTrials.gov serves as the primary registry for clinical trials conducted under FDA oversight.

Huntington Disease Ultrasound Trial, Fujian Medical University

Fujian Medical University registered a Phase 1/2 clinical trial (NCT07513844) on ClinicalTrials.gov investigating low-intensity ultrasound as a treatment for Huntington disease. The trial will assess safety and preliminary efficacy parameters in patients with the neurodegenerative condition. ClinicalTrials.gov serves as the primary public registry for clinical research conducted under FDA oversight.

Medicare Prior Authorization WISeR Model Correction Notice

CMS issued a correction notice to fix typographical and technical errors in the July 1, 2025 Federal Register notice about the WISeR (Wasteful and Inappropriate Services Reduction) Model for Medicare prior authorization. The corrections update specific lists of procedure codes for epidural steroid injections, vertebral compression fracture procedures, fusion procedures, and apnea treatments, while also clarifying applicability language for skin and tissue substitutes. The corrections are effective April 6, 2026, with applicability to January 1, 2026.

CMS Proposes Skilled Nursing Facilities Payment Updates for FY 2027

CMS has published a proposed rule (CMS-1843-P) updating the Skilled Nursing Facility Prospective Payment System rates and policies for fiscal year 2027. The rule also proposes updates to the SNF Quality Reporting Program and SNF Value-Based Purchasing Program requirements. Comments must be submitted by June 1, 2026.

ASP Data Submission Notice for Medicare Part B Drugs - Comments Closed May 7

CMS published a 30-day Paperwork Reduction Act notice announcing revision of an existing collection for manufacturer submission of Average Sales Price (ASP) data for Medicare Part B drugs and biologicals. The notice revises the Bona Fide Service Fee Certification form and updates burden estimates. Comments on the information collection must be received by the OMB desk officer by May 7, 2026.

Medline Convenience Kits containing Namic RA Syringes recall - death risk

Health Canada issued a Type I recall for Medline Convenience Kits containing Namic RA Syringes due to a potential risk of the syringe rotating adaptor unwinding during use, which may cause procedural delays or, in severe cases, death. Multiple lot numbers across angiographic kits, convenience kits, and tumescent syringe kits are affected. Healthcare providers have been advised to immediately stop using and discard the affected syringes.

Adaptive proton therapy pediatric solid tumors Hodgkin's lymphoma

ClinicalTrials.gov registered a new Phase 2 interventional study (NCT07514819) evaluating adaptive proton therapy for pediatric patients with solid tumors and Hodgkin's lymphoma. The single-arm trial will assess treatment response rates, survival outcomes, and treatment-related toxicity in pediatric oncology patients. The study is sponsored by the University of Pennsylvania and will enroll approximately 40 participants.

MR-guided adaptive stereotactic radiotherapy for endometrial cancer, Radboud University

The National Library of Medicine registered a new clinical trial (NCT07514325) on ClinicalTrials.gov studying MR-guided adaptive stereotactic radiotherapy for endometrial cancer. The single-arm study will enroll an estimated 20 participants at Radboud University Medical Center in the Netherlands to evaluate feasibility and toxicity outcomes of adaptive radiotherapy guided by MRI imaging.